Orange Health’s Growth Comes With Steepening Losses
Orange Health’s diagnostics expansion drove FY26 operating revenue up 65% to Rs 138.6 crore, with more than 60 company-owned collection centres added and coverage extending across tier I cities. But the growth came at a high cost: expenses reached Rs 240.3 crore and the company reported a Rs 146 crore overall loss, making its planned $30 million raise key to its FY27 trajectory.
Thursday, Aug 20, 2026
Tracking: Y Combinator
Geography: San Francisco Bay Area, Silicon Valley, United States
1. Orange Health reports Rs 138.6 crore FY26 revenue as losses widen
Y Combinator-backed Orange Health grew revenue from operations 65% to Rs 138.6 crore in the fiscal year ended March 2026, as its Bengaluru diagnostics business expanded across tier I cities.
The company added more than 60 company-owned collection centres, nearly 50 in Bengaluru, and serves consumers through on-demand testing and at-home sample collection while supporting more than 2,000 clinics. Expansion came with heavy costs.
Orange Health’s expenses rose 36% to Rs 240.3 crore, producing a Rs 97 crore loss before tax and a Rs 146 crore overall loss after deferred tax.
The company is raising $30 million, following nearly $50 million in earlier funding; the new capital is expected to affect FY27 results.
Key facts:
Revenue from operations rose to Rs 138.6 crore in FY26, from Rs 84 crore.
Loss before tax increased 11% to Rs 97 crore; overall loss reached Rs 146 crore.
Orange Health added over 60 company-owned collection centres, nearly 50 in Bengaluru.
The company is raising $30 million after nearly $50 million previously raised.
Employee benefits cost Rs 72.2 crore, up 43% year-on-year.
Why it matters: Orange Health’s results show the trade-off in building a vertically integrated diagnostics network: revenue grew quickly, but staffing, testing materials, claims contracts and overheads pushed expenses far above sales.
Its reported 20% EBITDA profitability in Bengaluru contrasts with a company-wide EBITDA margin of negative 66.68%, suggesting that performance varies sharply by market as expansion continues.
The $30 million round gives Orange Health additional capital for its next phase, but also raises the stakes around improving unit economics.
The competitive benchmark is demanding: PharmEasy-owned Thyrocare reported Rs 829 crore in FY26 revenue and Rs 163 crore profit, while Healthians reported Rs 263 crore revenue and a Rs 5 crore loss in FY25.